Background. Cryptococcus gattii (Cg) infection emerged in British Columbia in 1999. A longitudinal, clinical description of patients has not been reported.
There is a wide spectrum of illness, an observation facilitated by the inclusion of non-culture-confirmed cases and outpatient cases (often asymptomatic or with mild symptoms) in BC surveillance [5, 6] . These findings are based on self-reported data collected during detailed public health interviews. To date, no information has been published on the clinical progression and outcome of these cases in BC.
There have been very few longitudinal studies of C. gattiiinfected individuals or studies assessing predictors of mortality [7] [8] [9] . Most of these have been conducted in Australia where the predominant C. gattii strain (VGI) is different from that in BC (VGIIa) and where patients are more likely to present with CNS disease. A US study included cases that are part of the same disease emergence as in BC (VGIIa) but also other strains and cases from outside the Pacific Northwestern United States [8] . In these studies, only culture-confirmed cases have been included and the number of deaths has been small, limiting the power to identify predictors. The adherence to and impact of treatment guidelines [10, 11] and the clinical course have previously been reported for C. gattii infection from Australia [12] and the US Pacific Northwest [13] .
We undertook a retrospective chart review of C. gattii cases in BC from 1999 to 2007 to describe the spectrum of disease and course of illness over time and to identify predictors of mortality.
METHODS
Eligible patients included those reported to the BC Centre for Disease Control between January 1999 and December 2007. Culture-confirmed C. gattii was diagnosed by growth of Cryptococcus isolates on differential medium (L-canavanine-glycinebromothymol blue medium) and subsequently confirmed by restriction fragment length polymorphism methods [14] at the BC Public Health Microbiology and Reference Laboratory. Individuals with cryptococcosis (unconfirmed Cryptococcus species) diagnosed by histopathology, serology (IMMY LatexCryptococcus Antigen Detection System, Immuno Mycologics, Inc), or microscopy who were human immunodeficiency virus (HIV) negative and exposed to an endemic area within 12 months of diagnosis were considered probable cases [5] . Probable cases in this study were further restricted to those without other causes of immunocompromise (see study definitions in Supplementary Table 1) . Approval to conduct a retrospective chart review was obtained from the St Paul's Hospital/University of British Columbia ethics board, and relevant regional health authority ethics boards.
Inpatient and, when necessary, outpatient medical charts were reviewed in hospital medical records departments and in outpatient care facilities, respectively. A standardized case report form was used to collect clinical, laboratory, and imaging data. Whenever documented in the patient chart, clinical outcomes (complete response, partial response, stable disease, progressive disease, relapse, and death due to C. gattii or where C. gattii contributed) and their associated assessment dates were collected. Death information was collected from the hospital or outpatient medical record. Date of diagnosis was used as time zero for the study. Two chart abstractors were trained by a single investigator, and each case report form was reviewed by that same investigator prior to entry into a Microsoft Access database.
The duration of antifungal therapy was calculated after excluding patients who had no record of receiving treatment (n = 26) and patients with any missing antifungal therapy start or end dates (n = 35). To avoid treatment durations shortened prematurely by death, patients for whom the interval between antifungal therapy discontinuation and death was <30 days were also excluded (n = 22).
Clinically relevant predictors of C. gattii mortality were examined using a series of single-predictor Cox regression models for time to death (censored at the end of study or lost to followup), followed by a multivariate Cox regression model including all predictors.
Survival outcomes were summarized graphically using cumulative incidence curves calculated under a competing risks framework. Cases with no follow-up clinical information beyond diagnosis were excluded from all time-to-event analyses. Cubic B-splines were used in mixed-effects regression models to obtain estimates of serum cryptococcal antigen (SCrAg) titer levels and the probability of the presence of cryptococcoma on chest imaging over time (either present from initial diagnosis or detected at a later date).
All analyses were conducted using SAS version 9.3 and R version 2.15. No corrections have been applied to account for multiple testing; hence, P values should be interpreted as exploratory.
RESULTS
One hundred fifty-two cases were included in the analysis; 111 (73.0%) were culture confirmed and 41 (27.0%) were probable ( Figure 1 ). Among probable cases, 33 (80.5%) were diagnosed by histopathology, with or without CrAg, and the remaining 8 by CrAg alone. Results differed little between all cases and culture-confirmed cases only, so the discussion focuses on results for all cases.
Demographics, Sites of Infection, and Underlying Conditions
One hundred five cases (69.1%) presented with a lung infection only; the other 47 had CNS infection with or without lung infection ( Table 1) . Exclusion of CNS infection by lumbar puncture was documented in 28 of the 105 (26.7%) cases in the lung infection only group. Cases with lung infection only were more likely to be older (P = .008), have an underlying medical condition (P = .013), and have a past history of smoking (P < .001). Overall, 23 of the 111 (20.7%) culture-confirmed cases were considered to be immunocompromised, including 5 (4.5%) with HIV infection.
Approximately one-third (37/105 [35.2%]) of isolated lung cases compared with 8.5% (4/47) of CNS cases were culture negative (P < .001). All of the C. gattii-related mortality occurred in the culture-positive group (24/111 [21.6%] vs 0/41; P < .001). Among the culture-confirmed cases, the vast majority (94/111 [84.7%]) were infected with C. gattii VGIIa. Patients infected with VGI were more likely to have CNS infection (P = .028; Table 1 ).
Signs and Symptoms
Fever was the most frequent constitutional symptom, but only reported in about one-third (45/152 [29.6%]) of all cases (Table 2 ). Spinal fluid opening pressure measurements were elevated (>20 cm water) in 21 of the 27 (77.8%) CNS patients who had measurements recorded.
Imaging Findings
The first available chest imaging showed cryptococcomas (single or multiple) in 99 of 149 (66.4%) patients who had results available ( Table 3 ). The first available brain imaging showed cryptococcomas in 8 of the 43 (18.6%) CNS cases who had results available (Table 3 ). An additional 9 other CNS patients 
Provisional Diagnosis
Among all 152 patients, the provisional diagnosis was neoplasm for 42.1% (n = 64) and pneumonia for 23.0% (n = 35). Among 47 patients with CNS infection, 27.7% (n = 13) had a provisional diagnosis of neoplasm, 17.0% (n = 8) meningitis, and 10.6% (n = 5) pneumonia.
Treatment and Adherence to Guidelines
All but 1 patient (46/47 [97.9%]) with CNS infection received antifungal treatment; documentation of antifungal treatment could only be confirmed for 76.2% (80/105) of patients with isolated lung infection (P < .001; Table 4 ). The 26 of 152 (17.1%) patients with no record of treatment included 5 with a late diagnosis (2 postmortem, 3 just prior to death at the time of palliative care), and 12 who underwent wedge resection biopsy or lobectomy for a suspected neoplasm. Among all 152 patients, there were 24 thoracic surgeries; 1 was primarily therapeutic, and the others were diagnostic. An approximation for adherence to treatment guidelines (defined in Supplementary Table 1) among 132 evaluable cases demonstrated an overall adherence rate of 78.8% (Table 4) .
Outcome and Mortality
Among all 152 cases, complete or partial response occurred in 26 of 45 (57.7%) CNS and 47 of 71 (66.2%) lung-only cases who had follow-up evaluations at 12 months (Table 4) . Cryptococcus gattii-related and all-cause mortality among culture-confirmed cases at 12 months' follow-up was 23.3% (24/103) and 27.2% (28/103), respectively. At 12 months' follow-up in the subgroup of patients with symptomatic, culture-positive infection, whose treatment was adherent to guidelines, the C. gattii-related and all-cause mortality was 23.3% (14/60) and 28.3% (17/60), respectively. Complete response was achieved uniformly throughout the 6 years of observation ( Figure 2 ). Two culture-positive relapses occurred among immunocompetent patients. One was initially treated for isolated lung infection (no headache or neurologic symptoms, but no lumbar puncture confirmation) with a 3-month course of fluconazole 400 mg/day, but subsequently developed meningitis. The second patient had recurrent meningitis after a 10-month course of treatment, which included only 6 days of amphotericin B induction followed by fluconazole. A third patient with culture-positive CNS and lung infection developed evidence of a culture-negative relapse 3 years after diagnosis, with recurrent headache and increase in size of multiple persistent cerebral cryptococcomas.
Among all patients, C. gattii caused or contributed to a fatal outcome in 17.6% (24/136), all within the first 12 months from diagnosis ( Figure 2 and Table 4 ). On multivariate analysis, those with C. gattii-related mortality were more likely to have been aged ≥50 years or immunocompromised (Table 5) .
Neurologic Findings and Complications
At diagnosis, 15 patients had neurological deficits and 4 had altered mental status (data not shown). New neurological complications developed in 29.8% (14/47) of patients with CNS infection, including 10 with altered mental status, 5 with focal neurological deficits, 2 with seizures, and 1 with hydrocephalus (Table 4) . Persistent neurological symptoms at the end of follow-up were found in 17.0% (8/47) of CNS patients, including 3 with gait or balance disturbance, 2 with partial hearing loss, 2 with cognitive impairment, 1 with blindness, and 1 with seizure disorder (data not shown). Immune reconstitution inflammatory syndrome developed in 17.0% (8/47) of patients with CNS infection, whose follow-up imaging showed new cryptococcomas, inflammatory brain lesions, or meningeal enhancement. Abbreviations: CNS, central nervous system; HIV, human immunodeficiency virus; NA, not applicable. a Other sites of infection among the CNS cases included blood (n = 4), urine (n = 1), and bone (n = 1) confirmed by culture; and skin (n = 1) and chest wall (empyema necessitans) (n = 1) demonstrated by histopathology. One of the 105 cases with lung infection was also culture positive from pleural fluid (fungal empyema). b P values are for comparison of CNS disease group vs lung-only group.
c Respiratory disease included chronic bronchitis, chronic obstructive pulmonary disease, pulmonary sarcoidosis, chronic suppurative lung condition, chronic lung disorder from dust exposure, asthma, emphysema, interstitial lung disease, previous hyaline membrane disease, bronchiectasis, pulmonary stenosis, and pulmonary fibrosis. Figure 1) . The association between duration of SCrAg positivity (any titer) and the recorded duration of antifungal therapy was not significant (Spearman ρ = 0.223, P = .213) for the 33 probable and confirmed cases who had serial SCrAg titer available. The estimated probability of detecting a chest cryptococcoma was 77.8% at diagnosis and 69.2%, 47.9%, and 27.4% at 1, 3, and 5 years after diagnosis, respectively (Supplementary Figure 2) .
DISCUSSION
This is the largest case series of culture-confirmed infection (n = 111) due to C. gattii, and includes 41 (26.9%) nonimmunocompromised culture-negative probable cases, based on histopathology and/or serology. Only 30.9% of cases in BC had CNS infection with or without associated lung cryptococcosis. This contrasts with the experience recently published by US and Australian investigators who observed CNS infection among 49% and 85%, respectively, of C. gattii-infected patients [8, 9] . The higher rate of CNS infection in the Australian series is likely related to the predominant Australian genotype VGI, which was also associated with CNS involvement in our series, but accounted for only 5.4% of BC cases. The higher rate in the US study may reflect differences in case ascertainment, with our study including a larger proportion of asymptomatic cases as well as culture-negative probable cases, who were more likely to have pulmonary rather than CNS disease. Inclusion of the culture-negative probable C. gattii cases provides further insight into the spectrum of disease. This is the first large case series to include the provisional diagnosis, which was most often malignancy. A clinical presentation with nodular mass lesions in lung and/or brain with no history of fevers would raise suspicion of a malignant rather than infectious process, and may contribute to delay in diagnosis.
Although SCrAg is an excellent diagnostic test, serial monitoring of SCrAg in AIDS-related cryptococcal meningitis has not been helpful for the purpose of confirming either clinical response or relapse [15] . We are not aware of other studies describing serial monitoring of SCrAg in C. gattii infection. Our findings indicate that SCrAg often remains positive for several b Neurological signs and symptoms at the time of diagnosis not presented include seizures (n = 3), obtundation (n = 3), papilledema (n = 2), and dementia (n = 1). c Based on patients for whom CSF pressure measurements were taken at any time and includes the highest value for those who had multiple measurements.
years, and we were unable to demonstrate an association between duration of antifungal therapy and the duration of SCrAg positivity. Given the low rate of relapse or progressive disease, there appears to be no clear indication that a persistently positive SCrAg at the end of treatment (6-18 months for pulmonary or CNS disease in HIV-negative patients [11] ) is predictive of treatment failure. Our study mirrors previous small case series demonstrating that Cryptococcus neoformans cryptococcomas may persist for years after completion of ultimately successful antifungal therapy [16] . Cryptococcus gattii cryptococcomas in lung or brain were slow to resolve (median of 2.8 years for lung lesions), and, like SCrAg, often persisted in the absence of subsequent clinical relapse following discontinuation of antifungal therapy.
The proportion of asymptomatic cases (15.1% overall and 21.0% in lung only cases) is higher than previously reported in BC (7.3%) [5] but consistent with other studies of pulmonary cryptococcosis (all species) that have reported a proportion of asymptomatic cases of 14%-38% [17] [18] [19] [20] . Asymptomatic infections in our study were generally confined to the lung (95.6%), occurred in immunocompetent patients (87.0%), had a provisional diagnosis of neoplasm (82.6%), and were not fatal.
All-cause mortality at 12 months for culture-confirmed cases in BC was 27.2% (28/103) for all cases, 30.2% (13/43) for CNS cases, and 25% (15/60) for lung-only cases. The corresponding Australian mortality rates were 13.6% for CNS disease and 11% for pulmonary cases [9] ; the overall US culture-confirmed mortality was 33% [8] . A somewhat smaller proportion of BC cases (74%) were hospitalized in our series compared with US cases (91%), suggesting that differences in case ascertainment may have resulted in the inclusion of more severe disease and a higher risk of death in the US study.
We found that advancing age and immunocompromise were associated with increased C. gattii-related mortality, which occurred almost entirely within the initial 6 months after diagnosis. Two other studies in the United States and Australia have examined predictors of mortality in C. gattii populations, but have done so for all-cause mortality [8, 9] . There was a trend b P values refer to the comparison between patients with CNS disease (with or without lung disease) and lung-only disease. toward CNS involvement predicting C. gattii death in BC, but the presence of CNS symptoms was negatively associated with all-cause mortality in the US study. All 3 studies present conflicting results with respect to the role of immunocompromise, likely due to differing study definitions. A future study combining C. gattii infection data from all 3 regions will increase the power to detect predictors of mortality.
Adherence to treatment guidelines for culture-confirmed cases with CNS disease (induction therapy with an amphotericin B formulation, rather than only fluconazole) was higher in the Australian series (88%) than in BC (70% [28/40]). In a recent study from the US Pacific Northwest, Smith et al [13] demonstrated a trend toward increased 3-month mortality in C. gattii infections treated with alternative initial treatment Table 1 for adherence definition. Twenty patients were excluded from this analysis, including 13 with missing antifungal start or stop dates for induction therapy, 5 diagnosed postmortem or at the time of palliative care, and 2 who died before the third day of amphotericin B induction therapy. c See "Methods" section for exclusions from duration of antifungal therapy calculation.
d Therapeutic neurosurgical procedures included brain mass lesion decompression (n = 2) and spinal fluid drainage procedure (n = 7 [14.9%] ).
e Respiratory complications (n = 9) included empyema necessitans due to C. gattii (n = 1), ventilatory support for airway protection (n = 1) or respiratory failure due to C. gattii (n = 3), or additional respiratory disorders (n = 4). f Outcome at 12 months (see definition in Table 1 ).
g Exceptions were made in classifying these cases as relapsed: 1 case relapsed and then was considered progressive, both shortly before 12 months. The other relapsed 1 day after being considered progressive closer to the 12-month mark. h Other causes of death included chronic lymphocytic leukemia, metastatic lung cancer, lymphoma, congestive heart failure, and acute respiratory distress syndrome due to aspiration pneumonia. i Subsequent follow-up evaluation after the 12-month window indicated survival beyond the 12-month window.
j These cases had no outcome documented (n = 16).
compared with recommended initial treatment, based on Infectious Diseases Society of America (IDSA) guidelines [10, 11] . This was primarily related to mortality in severe pulmonary infection. Comparisons regarding adherence to guidelines between this study and ours are limited by differences in definitions. However, all of the patients with CNS infections in the US study received an induction regimen that included amphotericin B. In contrast to our study, adherence to guidelines in this US study was greater for CNS than lung infections [13] . The absence of an association between adherence to IDSA guidelines and mortality in our study may be related to confounding factors inherent in the observational study design. Limitations include the retrospective study design with incomplete data on some patients, including long-term outcome. However, given the presence of a provincial surveillance system and the inclusion of cases from all major hospitals in the study region, it is unlikely that a significant number of additional patients had progressive disease and unfavorable outcomes and were not captured. The inclusion of probable cases was both a strength and a weakness of the study. Although a few patients with disease due to C. neoformans may have been misclassified in the probable group, previous BC studies have provided evidence that most probable cases are likely infected with C. gattii. In particular, cryptococcosis hospitalization rates among HIV-negative individuals (ie, probable cases) increased in C. gattii-endemic areas at the onset of the epidemic, but remained constant in nonendemic areas [21] .
CONCLUSIONS
This study has characterized the spectrum of clinical disease due to C. gattii in British Columbia, ranging from a solitary asymptomatic pulmonary nodule to fatal disseminated disease. Table 5 , where the window for the outcome at 12 months spanned 10-18 months. Abbreviations: CG Death, death related to C. gattii infection (see definitions, Table 1 ); Comp Resp, complete response; Non-CG Death, death unrelated to C. gattii infection. Abbreviations: CI, confidence interval; CNS, central nervous system. a Reference category includes cases who were not immunocompromised and had no underlying conditions.
b Includes patients with immunocompromising conditions (as defined in Table 1 ) with or without other underlying conditions.
c Includes patients who have at least 1 underlying condition but who are not immunocompromised. This includes patients with chronic liver disease, chronic cardiovascular disease, chronic renal disease, chronic respiratory disease, diabetes mellitus, chronic anemia, solid tumor malignancy, and other specified underlying conditions.
Mass lesions on imaging combined with the absence of fever frequently resulted in a provisional diagnosis of malignancy. All C. gattii-related mortality was observed within the first year following diagnosis, and was predicted by advancing age and immunocompromise. Resolution of imaging abnormalities and cryptococcal antigenemia was frequently slow, over months to years. However, late onset of failed therapy or relapse was uncommon, suggesting that the delayed resolution of these findings does not require prolongation of treatment beyond the duration recommended by guidelines, unless clinical or microbiologic indicators of failed therapy are present.
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